PMID
int64 35.7M
36.4M
| Title/Abstract
stringlengths 22
8.78k
| MeshTerms
stringlengths 7
101
| SemanticTypes
stringlengths 4
64
|
|---|---|---|---|
36,270,951
|
comparison fix live cell base assay detect achr musk antibodi myasthenia gravi live cell base assay cba detect acetylcholin receptor achr muscl specif tyrosin kinas musk antibodi ab proport patient radioimmunoassay ria doubl seroneg myasthenia gravi dsn mg commerci fix cba achr musk ab recent becom avail howev compar studi fix live cbas lack studi compar perform fix live cbas patient ria dsn mg assess sensit ria posit mg sampl specif
|
D009157;D020794
|
T047;T126;T116;T192
|
36,270,950
|
multipl sclerosi follow neuromyel optica spectrum disord nation multipl sclerosi societi case confer proceed woman present age year partial myeliti diplopia experienc multipl subsequ relaps mri demonstr abnorm characterist multipl sclerosi ms white matter ovoid lesion dawson finger csf demonstr elev igg index oligoclon band restrict csf diagnos clinic definit relaps remit ms treat various ms diseas modifi therapi eventu began experienc secondari progress age year develop acut longitudin extens transvers myeliti found aqp antibodi cell base assay analysi clinic cours radiograph find molecular diagnost method treatment respons characterist support hypothesi patient like cns inflammatori disord ms manifest teenag neuromyel optica spectrum disord evolv sixth decad life case emphas key principl neurolog practic reconsid whether origin work diagnosi remain tenabl especi confront evid clinic andor paraclin rais possibl distinct differ disord
|
D009471;D009103;D009188
|
T047
|
36,270,901
|
physic activ exercis capac mortal risk peopl interstiti lung diseas systemat review meta analysi physic activ exercis measur show potenti predict mortal peopl interstiti lung diseas studi summar evid associ physic activ exercis capac measur mortal risk peopl interstiti lung diseas quantifi magnitud meta analysi
|
D017079;D017563
|
T201;T047
|
36,270,893
|
synthesi character superoxid dismutas activ biomimet mn iii complex coval anchor mesopor silica mononuclear mn iii complex clickabl ligand mn hbpapn h clo h h hbpapn bis hydroxybenzyl propargyl amino propan prepar fulli character complex catalyz dismut superoxid employ mn iii mn iv redox cycl catalyt rate constant determin nitro blue tetrazolium photoreduct inhibit assay aqueous medium ph alkyn function ligand use coval attach catalyst azid modifi mesopor silica differ textur morpholog click chemistri materi catalyst essenti link inner pore wall isol protect extern medium hybrid materi recycl retain improv superoxid dismutas activ free catalyst pore size solid matrix play role activ catalyst
|
D008345;D012822
|
T123;T196;T197
|
36,270,892
|
challeng best practic lesson learn oral cholera mass vaccin campaign urban cameroon covid era sinc cameroon face ever grow seri cholera epidem despit effort made govern address substanti public health problem addit covid pandem cameroon record high cholera case fatal rate follow epidem note south littor south west region far higher world health organ accept rate
|
D002771;D022121;D000086382
|
T129;T047;T121;T067
|
36,270,891
|
evalu correl protect mix match vaccin covid voc potenti evad immun face rapid emerg variant concern voc potenti evad immun beta omicron uneven distribut differ vaccin brand mix match strategi consid enhanc immun howev whether increas immunogen use mix match lead high clinic efficaci particular face omicron pandem still remain elus without use tradit phase trial aim studi demonstr evalu correl protect cop mix match vaccin
|
D000086382;D007252
|
T129;T121;T067;T109;T047
|
36,270,763
|
comprehens geriatr assess cga periop care systemat review complex intervent comprehens geriatr assess cga complex intervent appli older peopl evid benefit medic popul aim systemat review describ cga appli surgic popul randomis control trial provid basi design futur studi focus optimis cga complex intervent
|
D006620;D005853
|
T090;T091;T037
|
36,270,762
|
covid vaccin status associ factor among lactat women covid outbreak cross section studi southern china differ countri institut around world debat whether lactat women receiv covid vaccin covid pandem china lactat contraind vaccin mani women still hesit get vaccin purpos studi investig current status covid vaccin among lactat women relat factor affect vaccin
|
D000086382
|
T047;T067
|
36,270,761
|
impact introduc non clinic communiti health advic navig servic demand primari care social depriv area evid observ panel studi differ differ design examin effect introduc non clinic communiti health advic navig servic demand primari care social depriv area
|
D011634;D058005
|
T091;T097
|
36,270,760
|
mesenchym stem cell effect allerg rhiniti protocol systemat review meta analysi allerg rhiniti ar kind widespread unrecognis inflammatori disord nasal mucosa characteris itch sneez runni nose nasal congest efficaci mesenchym stem cell mscs treatment ar remain controversi protocol describ systemat review meta analysi approach assess efficaci safeti mscs treatment ar
|
D065631;D059630
|
T047;T025
|
36,270,759
|
communiti determin copd exacerb elder patient lodz provinc poland retrospect observ big data cohort studi evalu preval identifi demograph econom environment local communiti determin chronic obstruct pulmonari diseas copd exacerb elder primari care use big data approach
|
D000077558;D029424
|
T047;T170
|
36,270,758
|
effect reduc sedentari behaviour durat increas physic activ cognit function brain function structur across lifespan systemat review protocol greater engag sedentari behaviour relat poorer cognit function epidemiolog research howev effect reduc sedentari behaviour durat cognit function brain function structur remain poor understood systemat review aim synthesis evid effect reduc sedentari behaviour durat increas time spent physic activ cognit function brain structur function appar healthi children adolesc adult
|
D057185;D008136
|
T033;T102;T079
|
36,270,757
|
taysid screen cardiac event tascforc studi prospect cardiovascular risk screen studi risk factor base model struggl accur predict develop cardiovascular diseas cvd level individu way identifi peopl low predict risk develop cvd would allow stratifi advic support inform treatment decis initi adjust prevent medic aim prospect cohort studi
|
D002318
|
T047
|
36,270,756
|
lactat enhanc prognost accuraci quick sequenti organ failur assess adult patient sepsi systemat review investig whether ad lactat quick sequenti sepsi relat organ failur assess qsofa improv predict mortal adult hospit patient compar qsofa alon
|
D063305;D018805
|
T033;T081;T046;T047
|
36,270,755
|
cohort profil echo prenat earli childhood pathway health consortium echo pathway exposur earli life begin utero long term impact mental physic health echo prenat earli childhood pathway health consortium echo pathway establish examin independ combin impact pregnanc childhood chemic exposur psychosoci stressor child neurodevelop airway health well placent mechan under associ
|
D004781;D011297
|
T037
|
36,270,754
|
experi respons randomis control trial extend releas inject buprenorphin versus sublingu tablet buprenorphin oral liquid methadon opioid use disord protocol mix method evalu opioid use disord oud debilit persist disord standard care treatment daili mainten dose sublingu buprenorphin bup sl oral methadon met month extend releas subcutan inject buprenorphin bup xr develop enhanc treatment effect studi aim investig experi particip offer bup xr evalu health relat qualiti life among particip opt receiv bup xr longer term evalu experi particip alloc receiv bup xr bup sl met offer adjunct personalis psychosoci intervent evalu
|
D002047;D009293
|
T121;T048;T109
|
36,270,753
|
safeti toler pharmacokinet preliminari antitumour activ antisens oligonucleotid target stat danvatirsen monotherapi combin durvalumab japanes patient advanc solid malign phase studi assess safeti toler pharmacokinet preliminari antitumour activ pharmacodynam danvatirsen antisens oligonucleotid target signal transduc activ transcript stat monotherapi danvatirsen plus durvalumab antiprogram cell death ligand monoclon antibodi patient advanc solid malign
|
D000971;D009369;D016376
|
T061;T123;T191;T114;T130
|
36,270,752
|
factor affect delay present breast cancer symptom among women gaza occupi palestinian territori cross section survey identifi factor relat women delay present breast cancer symptom improv diagnosi occupi palestinian territori opt
|
D001943
|
T191
|
36,270,747
|
use bdmard tsdmard manag inflammatori arthriti checkpoint inhibitor observ studi limit experi regard use biolog diseas modifi antirheumat drug bdmard jak inhibitor jaki manag immun checkpoint inhibitor ici induc inflammatori arthriti aim assess efficaci safeti set
|
D018501;D000075242;D001172
|
T121;T047
|
36,270,744
|
sacroiliac joint radiograph progress axial spondyloarthr retard therapeut use tnf inhibitor year data scqm registri analys effect tumour necrosi factor inhibitor tnfi sacroiliac joint sij radiograph progress axial spondyloarthr axspa
|
D025241;D000089183
|
T047
|
36,270,743
|
risk lung cancer rheumatoid arthriti relat autoantibodi posit smoke lung cancer common malign rheumatoid arthriti ra sinc smoke risk factor seroposit ra lung cancer remain unclear whether ra increas lung cancer risk
|
D008175;D001172
|
T047;T191
|
36,270,742
|
radiolog evolut spinal diseas alkaptonuria effect nitisinon ochronot spondyloarthropathi repres one main clinic manifest alkaptonuria aku howev prospect data descript effect nitisinon treatment lack
|
D000474;D054850;D013122
|
T047
|
36,270,741
|
associ differ infect profil one year outcom anca associ vascul retrospect studi month infect screen studi aim explor clinic featur earli infect patient antineutrophil cytoplasm antibodi associ vascul aav identifi associ infect profil patient aav first month year surviv
|
D019268;D056648
|
T129;T047;T116
|
36,270,740
|
differenti expans peripher helper cell earli rheumatoid arthriti osteoarthr synovium program cell death protein pd express cell implic pathogenesi autoimmun inflammatori diseas rheumatoid arthriti subset cxcr cell term peripher helper tph cell drive b cell differenti identifi ectop lymphoid structur establish rheumatoid arthriti synovi tissu aim characteris treatment nave earli rheumatoid arthriti determin whether cell accumul prior fulli establish diseas
|
D001172;D010003
|
T047
|
36,270,739
|
synovi chondromatosi flexor halluci longus tendon sheath case report discuss rare case secondari tenosynovi chondromatosi flexor halluci longus fhl synovi chrondomatosi rare benign prolif cartilagin lesion aris synovi tissu bursal line near joint extra articular consid tenosynovi chondromatosi diagnosi often delay given rariti present non specif symptom case high unusu hindfoot pain caus sever centimetr size osteochondr bodi within fhl tendon sheath anterior cheilectomi perform patient return full activ follow surgeri without recurr diseas condit success treat oper
|
D015838;D018210
|
T047;T191
|
36,270,738
|
plaqu ruptur neovascularis detect optic coher tomographi case kouni syndrom kouni syndrom allerg acut coronari syndrom ac characteris coronari arteri spasm plaqu erosionruptur stent thrombosi caus mast cell interact cell activ although intracoronari imag modal detect ac mechan kouni syndrom due plaqu ruptur rare report use intracoronari imag present case woman develop kouni syndrom result plaqu ruptur detect optic coher tomographi oct non st segment elev ac result anaphylaxi cefazolin coronari angiographi reveal sever stenosi left anterior descend arteri angiograph undetect plaqu ruptur detect use oct oct also reveal intraplaqu neovascularis suggest culprit plaqu vulner oct aid understand under mechan kouni syndrom
|
D000074962;D058226;D054058
|
T047;T046;T020;T031
|
36,270,737
|
kidney transplant hiv posit deceas donor hiv posit recipi preliminari data hiv posit donor hiv posit recipi kidney transplant suggest promis patient outcom without advers event import step expand donor pool opportun transplant hiv posit patientsw herein report first case hiv posit donor hiv posit recipi kidney transplant denmark patient demonstr success post transplant cours excel year graft function reject episod good virolog control undetect hiv rna sign hiv associ nephropathi superinfect opportunist infectionsthi case corrobor find previous studi show kidney transplant care select hiv infect donor care select hiv infect recipi seem safe effect treatment option support opportun expand organ donor pool group patient end stage renal diseas
|
D016030;D007676;D015658
|
T061;T047
|
36,270,733
|
neoadjuv durvalumab resect non small cell lung cancer nsclc result multicent studi ifct ionesco ionesco ifct trial assess feasibl neoadjuv durvalumab earli stage resect non small cell lung cancer nsclc
|
D002289;D008175;D000074322
|
T121;T129;T191;T116
|
36,270,732
|
antitumor strategi target macrophag import consid differ differentiationpolar process human mous macrophag macrophag immun cell accumul major establish tumor accumul associ poor prognosi tumor associ macrophag tam produc inflammatori cytokin growth factor promot tumor expans metastasi tam recent emerg target choic restor effici antitumor respons limit tumor growth mani molecul target tam actual evalu clinic trial alon combin molecul induc tumor regress stimul cytotox respons mous model tumor develop result earli clinic trial less impress review list biolog differ human mous macrophag help explain differ efficaci antitumor strategi target tam human anim studi differ impact surviv polar factor cytokin produc marker express well limit extrapol base vitro model tam like generat consid order improv design efficaci antitumor drug target tam
|
D059016;D009369
|
T070;T191
|
36,270,731
|
combin precis oncolog immunotherapi target malt proteas innov strategi cancer therapi combin inhibit cancer cell intrins oncogen signal cancer cell extrins immunolog activ tumor microenviron tme general approach focus two distinct molecular target malign cell cell surround tme contrast proteas mucosa associ lymphoid tissu protein malt repres candid enabl dual approach engag singl target origin identifi clinic trial lymphoma drug target base role surviv prolifer malign lymphoma addict chronic b cell receptor signal malt proteolyt activ recent gain addit attent report describ tumor promot role sever type non hematolog solid cancer breast cancer glioblastoma besid cancer cell regulatori treg cell tme particular depend malt sustain immun suppress function malt inhibit select reprogram tumor infiltr treg cell foxp express proinflammatori antitumor effector cell therebi malt inhibit induc local inflamm tme synerg anti pd checkpoint blockad induc antitumor immun facilit tumor control reject new concept boost tumor immunotherapi solid cancer malt precis target tme enter clinic evalu dual effect malt inhibitor cancer cell immun cell therefor offer uniqu opportun combin precis oncolog immunotherapi simultan impair cancer cell growth neutral immunosuppress tme malt target may provid proof concept modul treg cell function tme repres feasibl strategi augment efficaci cancer immunotherapi review role malt proteas physiolog oncogen signal summar landscap tumor indic malt emerg therapeut target consid strategi increas chanc safe success use malt inhibitor cancer therapi
|
D009369
|
T191
|
36,270,728
|
liver transplant primari biliari cholang despit signific increas total number liver transplant lts perform last decad primari biliari cholang pbc becom uncommon indic lt like reflect benefit earlier diagnosi avail treatment ursodeoxychol acid udca nonetheless lt remain cure patient progress pbc despit medic therapi surviv rate among highest indic lt post lt pbc patient howev increas risk reject diseas recurr
|
D016031;D008105
|
T061;T047
|
36,270,727
|
novel therapi primari biliari cholang pipelin primari biliari cholang chronic autoimmun diseas character inflamm progress destruct small intrahepat bile duct current first line treatment includ ursodeoxychol acid howev signific number patient inadequ respons therapi patient risk liver failur requir liver transplant experi poor qualiti life due refractori symptom manuscript aim shed light current prospect treatment option may slow diseas progress improv patient symptom
|
D008105;D002761
|
T047
|
36,270,726
|
evalu manag pruritus primari biliari cholang chronic pruritus classic symptom patient primari biliari cholang affect two third patient cours diseas effici therapi consist topic treatment combin system option anion exchang rifampicin bezafibr opioid receptor antagonist select serotonin receptor uptak inhibitor gabapentinoid futur therapeut approach may contain select blockad enterohepat cycl inhibit ileal bile acid transport agon opioid receptor antagon mas relat g protein coupl receptor x nondrug treatment ultraviolet b therapi albumin dialysi biliari drainag avail special center
|
D008105
|
T047
|
36,270,725
|
treatment primari biliari cholang first line second line therapi primari biliari cholang pbc autoimmun diseas interlobular bile duct lead secondari damag hepatocyt may progress cirrhosi liver failur first line treatment ursodeoxychol acid patient adequ respons remain risk diseas progress obetichol acid condit approv treatment pbc add therapi bezafibr shown similar efficaci group patient sever new therapi develop may add treatment option avail patient pbc
|
D008105;D001327;D002761
|
T047
|
36,270,724
|
hepatocellular carcinoma primari biliari cholang hepatocellular carcinoma hcc potenti fatal complic affect patient primari biliari cholang pbc incid hcc per person year patient pbc cirrhosi much lower per person year among patient pbc without cirrhosi risk factor develop hcc pbc includ presenc advanc fibrosi cirrhosi male sex studi suggest treatment ursodeoxychol acid udca udca respons may reduc risk
|
D006528;D008105;D008113;D002761
|
T047;T191
|
36,270,723
|
noninvas evalu fibrosi portal hypertens primari biliari cholang primari biliari cholang pbc chronic cholestat liver diseas left untreat insuffici treat inexor progress toward cirrhosi potenti fatal complic alongsid biochem respons ursodeoxychol acid therapi advanc liver fibrosi portal hypertens ph shown major prognost determin pbc therefor one goal noninvas pbc evalu earli diagnos compens advanc diseas andor clinic signific ph articl main method noninvas assess liver fibrosi ph pbc clinic relev review
|
D008105;D006975
|
T047
|
36,270,722
|
inconveni truth primari biliari cholangitisautoimmun hepat overlap syndrom term pbcaih overlap appli featur autoimmun hepat aih biochem serolog histolog coexist primari biliari cholang pbc either first present sequenti diseas cours sever treatment paradigm propos extrapol primari condit howev randomis studi show improv surviv combin therapi compar bile acid monotherapi absenc high qualiti evid multidisciplinari patient specif approach must use individualis treatment pathway appreci diseas phenotyp alway static differ treatment respons potenti evolv time
|
D019693;D008105
|
T047
|
36,270,721
|
primari biliari cholang male pathogenesi clinic present prognosi primari biliari cholang pbc immun mediat chronic liver diseas character progress cholestasi bile duct destruct biliari fibrosi cirrhosi patient respond ursodeoxychol acid expect surviv similar general popul although pbc primarili affect femal preval male higher previous believ contemporari studi suggest femal male ratio diagnosi pbc often delay among male myth pbc rare male
|
D008105;D002779;D008107;D002761
|
T033;T047
|
36,270,720
|
prognost score system primari biliari cholang updat primari biliari cholang pbc complex chronic diseas heterogen present diseas progress respons therapi sever prognost model base diseas stage andor treatment respons enhanc risk stratif therapeut manag recent work diseas model propos earli predict outcom pbc onset yet implement clinic practic although earli stratif patient base individu risk develop end stage liver diseas may prove cost effect actual becom matter medic deontolog time offer best therapeut option given forthcom avail novel diseas modifi drug review outlin establish novel prognost system pbc provid perspect potenti role omic deriv biomark develop reliabl risk predict model promot implement person medicin pbc
|
D008105;D002761;D058625
|
T047
|
36,270,719
|
autoantibodi primari biliari cholang primari biliari cholang pbc chronic immun mediat liver diseas character lymphocyt cholang subsequ cholestasi progress liver fibrosi ultim complic aris end stage liver diseas test autoantibodi import diagnosi pbc well stratifi prognosi review focus role autoantibodi diagnosi pbc well relationship autoantibodi pathophysiolog prognost along discuss regard novel relat diseas autoantibodi
|
D008105;D002761;D002779;D008107
|
T033;T047
|
36,270,718
|
immunolog respons pathophysiolog primari biliari cholang primari biliari cholang pbc autoimmun liver diseas femal predisposit select destruct intrahepat small bile duct lead nonsuppur destruct cholang character seroposit antimitochondri antibodi pbc specif antinuclear antibodi progress cholestasi typic liver histolog manifest destruct protect bicarbon rich umbrella attribut decreas express membran transport biliari epitheli cell bec lead accumul hydrophob bile acid sensit bec apoptosi recent x wide associ studi reveal novel risk locus x chromosom reiter import treg cell
|
D008105;D002761
|
T047
|
36,270,717
|
genet primari biliari cholang primari biliari cholang pbc rare diseas liver character autoimmun attack small bile duct pbc complex trait mean larg list genet factor interact environment agent determin onset genom wide associ studi huge impact foster research pbc mani step need still done compar autoimmun diseas similar preval review present state art regard genet architectur pbc provid thought reflect possibl futur line research help fill miss herit gap pbc
|
D008105;D001327
|
T047
|
36,270,716
|
contemporari epidemiolog primari biliari cholang primari biliari cholang pbc cholestat liver diseas potenti evolut liver cirrhosi left untreat despit rare pbc substanti impact qualiti life surviv affect patient women diagnos worldwid howev male subject seem aggress diseas wors prognosi chang epidemiolog trend emerg pbc increas global preval slight smooth sex differ review present avail data incid rate preval pbc worldwid highlight geograph differ factor impact clinic outcom
|
D008105;D002761
|
T047
|
36,270,715
|
user experi imag qualiti influenc perform autom real time quantif left ventricular function handheld ultrasound devic diagnost accuraci studi data general practition nurs cardiologist echocardiographi cornerston heart failur hf diagnosi expertis limit non expert use handheld ultrasound devic hud challeng clinic yield left ventricular lv eject fraction ef use assess grade hf mitral annular plane systol excurs maps reflect lv long axi shorten automat tool quantif ef autoef maps automaps avail hud aim explor import user experi imag qualiti autoef automaps hud imag qualiti influenc feasibl agreement reliabl patient suspect hf
|
D000072096;D058005
|
T097
|
36,270,714
|
percutan left atrial appendag occlus discrep randomis trial clinic practic patient atrial fibril previous episod bleed oral anticoagul treatment left atrial appendag occlus laao emerg altern way decreas risk stroketh use procedur rise news coverag domin uncrit accept benefit procedur probabl contribut increas number proceduresthi commentari present critic apprais avail evid efficaci safeti left atrial appendag closur stroke prophylaxisw illustr laao support limit randomis data risk serious complic believ support current widespread use
|
D020517;D001281;D006348;D020521
|
T061;T023;T046;T047
|
36,270,713
|
coronari perfor incid outcom tempor trend copit systemat review meta analysi coronari perfor potenti life threaten complic percutan coronari intervent pci studi incid outcom tempor trend follow pci relat coronari arteri perfor cap
|
D062645;D006335
|
T061;T037
|
36,270,703
|
analysi potenti risk factor surviv patient primari retroperiton liposarcoma present work observ studi seri variabl regard overal surviv diseas free surviv patient diagnos primari liposarcoma
|
D009364;D008080
|
T191
|
36,270,702
|
incid risk factor incision hernia open abdomin aortic aneurysm repair incision hernia ih common open abdomin aortic aneurysm aaa repair recent studi report incid rate higher previous state aim studi quantifi ih incid open aaa surgeri secondari outcom identifi risk factor associ develop ih
|
D000069290;D017544;D051436
|
T047;T046
|
36,270,701
|
clinic effect safeti spinal anaesthesia compar general anaesthesia patient undergo hip fractur surgeri use consensus base core outcom set patient public inform outcom systemat review meta analysi randomis control trial conduct systemat review meta analysi contemporari rcts determin clinic effect spinal vs general anaesthesia sa vs ga patient undergo hip fractur surgeri use consensus base core outcom set outcom defin import patient public involv ppi initi
|
D000775;D006620;D003693;D058186
|
T061;T047;T037;T048
|
36,270,699
|
rescu treatment seizur cluster treatment seizur cluster endeavor prevent addit seizur avoid progress condit prolong seizur status epilepticus rescu therapi key compon seizur action plan sap individu seizur cluster three rescu therapi approv unit state treatment seizur cluster diazepam rectal gel midazolam nasal spray diazepam nasal spray diazepam rectal gel effect rescu therapi seizur cluster though adult adolesc may social reserv regard administr intranas deliveri midazolam diazepam promis altern rectal administr formul offer easi social accept administr exhibit rapid onset allow possibl self administr label benzodiazepin oral disintegr lorazepam intranas use intraven iv formul midazolam via nasal atom less well character regard bioavail toler compar approv agent
|
D008140;D013226
|
T121;T047;T109
|
36,270,698
|
electrograph seizur critic ill identifi treat critic ill patient seizur challeng articl author review avail data patient popul risk seizur prognost tool helpsb electrograph seizur various ictal interict continuum pattern latest definit associ risk ancillari test imag studi serum biomark invas multimod monitor also illustr differ patient scenario treatment outcom propos recommend target treatment electrograph seizur critic ill patient
|
D016638;D004569
|
T060;T047;T034
|
36,270,697
|
epilepsi older person epilepsi common older peopl yet optim manag seizur demograph often somewhat overlook popul age across world complex earli onset epilepsi thank live later life preval epilepsi older peopl escal rapid assess manag age group challeng seizur may present unusu way complex comorbid polypharmaci often character older age might make establish diagnosi epilepsi older person difficult drug choic treatment option often limit need specif tailor older individu care consider relev comorbid complex inter relationship epilepsi dementia vascular diseas older peopl would seem research prioriti might intervent help reduc advers outcom grow potenti vulner group
|
D000927;D004827
|
T033;T121;T047
|
36,270,696
|
preval diagnosi sexual dysfunct peopl epilepsi even though sexual dysfunct occur half peopl epilepsi pwe most report recogn treat sexual dysfunct common patient uncontrol epilepsi frequent seizur receiv enzym induc antiseizur medicin asm presenc under anxieti depress associ higher frequenc sexual dysfunct pwe even though evid limit newer non enzym induc asm larg caus sexual dysfunct multidisciplinari multiprong approach requir comprehens evalu manag sexual dysfunct pwe
|
D004827
|
T033;T047
|
36,270,695
|
emerg technolog epilepsi surgeri patient medic refractori epilepsi defin failur achiev seizur freedom adequ trial antiseizur medic consid earli surgic evalu achiev seizur freedom meaning seizur reduct goal surgic treatment signific improv qualiti life decreas diseas relat morbid mortal preoper work imag modal aid local epileptogen zone target surgeri resect seizur focus yield highest chanc seizur freedom howev mani promis minim invas noninvas treatment option develop recent year close intertwin technolog advanc serv viabl altern resect particular neuromodul ablat procedur also new treatment option develop new neuromodul target studi surgic treatment option thought select base patient individu diseas process prefer
|
D004827;D000069279
|
T033;T047
|
36,270,694
|
autism spectrum disord epilepsi autism spectrum disord asd first describ disord consist triad qualit impair social interact communic restrict repetit pattern behavior interest activ relationship asd epilepsi well document patient asd increas risk epilepsi epilepsi higher risk asd compar general popul diagnos epilepsi asd challeng exampl stereotyp behavior could mistaken asd stereotypi fact may due seizur fortun recent year gain better understand best antiseizur medic asm use vulner popul howev studi need understand best screen asd epilepsi various asd phenotyp peopl epilepsi especi due de novo genesmut well factor influenc fluctuat natur asd symptom eg seizur type frequenc syndrom asm
|
D000067877;D004827
|
T033;T047;T048
|
36,270,693
|
racial inequ epilepsi burden treatment race social construct deserv attent epilepsi inequ research articl provid overview contemporari frame race health highlight select literatur racial inequ epilepsi assess progress issu remain gap evid racial inequ epilepsi mount particular area concern greater burden epilepsi lower use specialti care standard advanc therapi among racial group compar white remain gap futur direct discuss
|
D063505;D004827
|
T033;T047;T054
|
36,270,692
|
evalu treatment psychogen nonepilept seizur patient psychogen nonepilept seizur pnes repres distinct challeng group among function neurolog symptom convers disord involv complex set symptom comorbid best evalu treat multidisciplinari team clinician multidisciplinari collabor care becom common use evid base treatment outpati neurolog clinic site current treat patient hold potenti provid model care coordin servic best practic care encourag integr neurolog mental health profession improv communic among clinician patient allow better patient care symptomat outcom
|
D003291;D009462
|
T091;T048
|
36,270,691
|
dietari treatment epilepsi ketogen diet one four major treatment epilepsi along antiseizur medic neuromodul surgeri ketogen diet therapi proven safe effect antiseizur regimen centuri multipl method administ diet initi individu patient diet shown effect treatment choic glut defici pyruv dehydrogenas defici infantil spasm superrefractori status epilepticus among other review discuss administr ketogen diet therapi highlight role specif epilepsi syndrom
|
D004827;D055423;D002239
|
T033;T047;T061
|
36,270,690
|
sleep epilepsi practic implic sleep restor balm mani often less peopl epilepsi complex bidirect interact sleep epilepsi detriment sleep epilepsi affect sleep state variabl activ eeg seizur occurr peopl epilepsi sleep disord high preval portend wors seizur epilepsi relat outcom random clinic trial sleep intervent epilepsi popul yet warrant given effect sleep dysfunct qualiti life risk sudep peopl epilepsi
|
D004827;D012893
|
T033;T047;T048
|
36,270,689
|
effect matern use antiseizur medic child develop children born women epilepsi wwe normal increas risk malform poor neuropsycholog outcom antiseizur medic asm among common prescrib teratogen medic women childbear age howev wwe typic avoid use asm pregnanc teratogen risk vari across asm valproat pose special risk anatom behavior teratogen risk compar asm risk mani asm remain uncertain women childbear potenti take asm take folic acid breastfeed take asm seem safe wwe receiv inform consent outlin risk concept
|
D011248;D004827
|
T033;T047;T046
|
36,270,688
|
updat sudden unexpect death epilepsi person epilepsi pwe fold increas risk die sudden unexpect compar general popul despit potenti prevent optim care sudden unexpect death epilepsi sudep one frequent caus death pwe especi children younger adult incid sudep general epilepsi popul rather consist per person year across seri sever risk factor sudep identifi focal bilater general tonic clonic seizur sleep alon signific therebi optim care nocturn surveil might decreas risk sudep final pwe want inform sudep provid inform might increas adher treatment therebi good seizur control narrat review provid updat sudep
|
D000080485;D004827
|
T033;T047
|
36,270,687
|
potenti wearabl devic mobil health applic evalu treatment epilepsi wearabl devic mobil health softwar applic great potenti improv epilepsi relat health outcom contribut person medic care person epilepsi limit challeng use track seizur occurr seizur detect predict forecast hospit ambulatori set also help promot self monitor self manag therebi contribut patient empower review provid overview current wearabl devic mobil health softwar applic epilepsi focus clinic valid devic clinic applic challeng face use devic real world set devic may optim futur
|
D000076251;D004827;D017216
|
T033;T047;T058;T073
|
36,270,686
|
telemedicin epilepsi care telemedicin method health care deliveri well suit epilepsi care insuffici suppli train specialist telemedicin hub spoke approach allow patient visit local health clinic spoke establish appropri care monitor seizur disord epilepsi remot connect epileptologist neurologist central center expertis hub covid pandem result expans telemedicin capabl use favor patient provid experi outcom allow wide scale adopt beyond covid
|
D000086382;D017216;D004827
|
T033;T047;T058;T067
|
36,270,685
|
epilept heart case routin use electrocardiogram patient chronic epilepsi dire complic associ chronic epilepsi abrupt prematur death current refer sudden unexpect death epilepsi sudep although tradit view sudep due primarili peri ictal respiratori failur lead cardiac asystol mount evid implic acceler heart diseas lead epilept heart condit especi age anoth potenti caus abrupt prematur death although cardiac death specif exclud standard definit sudep sudden cardiac death epilepsi carri fold greater risk general popul time frequent sudep review discuss rational routin use electrocardiogram assess cardiac risk patient epilepsi impact epilepsi treatment name antiseizur medic chronic vagus nerv stimul
|
D000080485;D004827;D055536
|
T033;T047;T061
|
36,270,683
|
overview cancer human microbiom mutual benefici associ microbi consortia essenti requisit human life microbi communiti symbiot pathogen standpoint portray context depend scenario human microbiom symbiot assemblag work develop indispens function human bodi immun system digest system defens colon pathobiont toxin etc furthermor deviat resourc util symbiont due host factor compris lifestyl chang diet drug immunocompromis state co morbid could perturb benefici microb communiti promot invas opportunist pathogen thus disrupt homeostat state microbi infest prove carcinogen spontan establish cancer hallmark rather initi cascad event disturb normal cellular activ final defect machineri invad distant site bodi submit devast transform intern milieu signific technolog system biolog advanc made elucid lucid complex basi microb associ malign chapter discuss recent advanc without compromis concept incept studi includ brief version microbi status cancer generat mechanist approach adapt therapeut intervent system biolog approach special mention studi design gap challeng address drawback final perspect futur target studi focus piec work
|
D064307;D009369
|
T001;T032;T191;T028
|
36,270,682
|
structur function divers healthi human microbiom taxonom composit function potenc microb associ differ part human bodi larg explor cultur independ metagenom sequenc divers microbiota live throughout human bodi made thousand microbi taxa three domain life archaea bacteria eukarya microbi load function potenc differ bodi site well distinct minim resembl higher taxonom level two habitat highest microbi load divers function potenc includ biosynthesi essenti nutrient chemic modif dietari compon sourc immunomodulatori molecul found gut microbiom howev inter individu divers dynam human microbiom given bodi habitat vari great time environment factor host genet contribut signific shape microbi communiti structur stabil basic understand nativ microbi composit function potenc stabil differ part healthi human live across geographi help us identifi diseas specif microbiota develop potenti microbiom base therapeut updat current understand divers dynam function potenc microbiom associ differ part human bodi
|
D064307;D000069196
|
T001;T032;T028;T007
|
36,270,681
|
emerg tool understand human microbiom recent advanc sequenc technolog experiment protocol approach data generat analysi enabl us investig human microbiom unpreced level resolut current chapter aim provid understand differ comput bioinformat strategi adopt answer differ question typic microbiom investig upstream dna sequenc methodolog affect chapter enlist state art metagenom data analysi along avail strategi perform integr investig human microbiom along data layer
|
D059014;D064307
|
T063;T032;T059;T028;T001
|
36,270,680
|
microbiom base therapeut opportun challeng autochthon microbi communiti compris symbiont commens opportunist pathogen live throughout human bodi profound contribut health reduc diseas suscept matur host immun communiti composit function repertoir microbiom present differ bodi habitat dynam structur function balanc human microbiom could modul environment factor lifestyl host genet sever function microbi communiti direct indirect modul host cellular signal pathway associ energi assimil sens respond environment signal neuroendocrin pathway resist colon allochthon microbiota diseas caus potenti cultur depend independ character microbi communiti composit function attribut help us recogn import microbi divers individu health identifi microb metabolit associ health diseas depth understand human microbiom creat avenu microbiom base translat research led discoveri develop larg number medic therapi chapter discuss current success microbiom base therapi infecti metabol diseas major bottleneck challeng translat research communiti symbiot microorgan
|
D064307;D019936
|
T001;T032;T028;T007
|
36,270,679
|
hepat drug metabol gut microbiom chapter focus intestin microbiota effect drug metabol discuss differ drug metabol either enzym gut microbiota mechan nowaday consum drug without doctor prescript common chapter make peopl awar negat consequ relat gut microbiota dysbiosi intestin disord like inflammatori bowel diseas ibd colorect cancer crc metabol disord obes type diabet mellitus td found affect gut microbiota dysbiosi address issu discuss varieti strategi fecal microbiota transplant fmt probiot antibiot stewardship program common use tackl problem
|
D000069196;D003924;D019936
|
T047;T007;T001
|
36,270,678
|
gut microbiom non alcohol fatti liver diseas human gastrointestin tract git contain dynam divers collect bacteria archaea fungi term gut microbiom gut microbiom major impact host homeostasi diseas connect host microbiom complex although manipul may assist prevent treat multitud morbid microorgan play critic role host energi metabol homeostasi accord new research microb gastrointestin tract play substanti role host health alter composit function might lead emerg metabol disord like non alcohol fatti liver diseas nafld resili git microbi ecolog toler perturb robust ideal sever factor may disrupt git microbiom homeostasi lead dysbiosi character imbalanc equilibrium perturb gut homeostasi irrit bowel diseas ibd malnutrit metabol disord nafld associ dysbiot gut microbiom recent evid suggest util medic prebiot probiot fecal microbiota transplant fmt manipul microbiom could viabl method treat nafld
|
D000069196;D065626;D019936
|
T047;T007;T001
|
36,270,677
|
gut microbiom type diabet dietari pattern excess calor shape complex metabol disord like type diabet td td involv complic metabol glucos lipid cholesterol storag along metabol dysregul system inflamm also reason insulin resist td import gut microbiota recent highlight establish link dietari pattern type bacteria overgrow modifi ferment bi product scfa secondari bile acid mucos immun cell chang direct impact liver metabol immun system result use pre pro biotic manag microbiota assist overcom lessen diseas symptom antibiot current employ produc germ free environ erad specif type bacteria order better understand role microflora chapter cover basic good bacteria well mechan work
|
D000069196;D003924
|
T047;T007;T001
|
36,270,676
|
gut dysbiosi metabol diseas disrupt composit gut microbi flora call gut dysbiosi associ pathogen implic number metabol disord type diabet mellitus non alcohol fatti liver diseas well atherosclerosi describ key find domain term gut dysbiot effect obesogen diet link metabol dysregul cross talk host genet gut ecolog preclin model metabol syndrom well human effect circadian rhythm gut microbiom regul system immunocellular respons particip metabol disord associ system inflamm gut microbiom metabolit deriv final collat evid gather till date specif gut dysbiot featur document differ compon metabol syndrom human understand gut dysbiosi metabol syndrom offer new insight pathogenesi specif clinic context well provid potenti new therapeut target warrant explor
|
D024821;D003924;D000069196;D008659
|
T047;T007;T001
|
36,270,675
|
gut microbiota gastrointestin diseas gut microbiota high dens popul differ kind bacteria resid gut co evolv host engag number metabol immunolog activ gut microbiota associ mainten health unbalanc microbiota contribut develop sever diseas alter benefici gut microbiota popul trigger gastrointestin diseas includ irrit bowel syndrom inflammatori bowel diseas celiac diseas colorect cancer mani other gut microbiota affect multipl factor diet stress genet variat chapter highlight gut microbiota play key role pathogenesi gastrointestin diseas
|
D000069196;D015212;D005767;D064307
|
T032;T007;T028;T047;T001
|
36,270,674
|
introduct human microbiom microbiom assemblag complex communiti microb bacteria archaea fungi alga protist virus biomolecul occupi well defin habitat live non live object environment expos surfac human bodi colon trillion microb three major domain life includ bacteria archea microscop eukarya howev rich abund function potenc microbi taxa live differ part human bodi distinct presenc common microbi taxa differ bodi habitat also rare recent develop next generat sequenc technolog establish indigen microbi communiti human bodi function attribut within given bodi habitat vari time ethnic group health status host perturb homeostasi communiti structur function due extrins factor alter mutualist host microb interact may lead diseas addit dysbiot state microbiom also affect efficaci therapeut prolong treatment durat lead undesir treatment outcom chapter structur function divers dynam human microbiom health diseas factor alter microbi composit interact microbi taxa xenobiot therapeut efficaci drug dysbiot condit highlight
|
D064307
|
T001;T032;T028
|
36,270,660
|
turn tide femal genit mutil high preval countri programmat data analysi sudan comprehens health sector respons sudan femal age year live femal genit mutil fgm most perform midwiv feder ministri health fmoh adopt global strategi stop healthcar provid perform fgm review activ report found format activ n main meet train median cost us us respect fmoh studentprofession associ implement activ nation state level cost activ highest fmoh compar studentprofession associ academia respectivelysudan address global strategi pillar fgm relat polici plan pillar train pillar monitor evalu account materi pillar target main communiti midwiv n well creat support legisl regulatori environ pillar government fund train compar donor result communiti midwiv train fgm complic manag communiti midwiv sign declar petit end fgm practic sensitis punit administr measur conduct fgmalthough sudan implement laudabl health sector respons address fgm need evalu qualiti effect past ongo intervent particular attent cost qualiti assur data essenti identifi cost effici implement approach reach remain sizeabl number health profession stop involv fgm
|
D019093
|
T061;T054
|
36,270,659
|
salari discret choic experi determin communiti health worker motiv work nigeria communiti health worker chws constitut major primari healthcar phc worker nigeria yet littl understood motiv effect intervent meet need ensur qualiti health coverag across countri aim identifi factor would motiv chws qualiti servic deliveri
|
D003150;D009042
|
T078;T080;T102;T097;T041
|
36,270,651
|
improv handwash among parent attend visit newborn unit practis famili participatori care newborn intens care unit nicu practis famili participatori care unit staff encourag parent attend sick newborn partner involv care babi remain concern practic may increas risk nosocomi infect carri unit parent attend staff observ handwash behaviour suboptim inconsist among parent attend facilit improv coach form qualiti improv team nicu staff improv hand hygien practic among attend baselin estim around attend adher hand hygien standard team plan reach target week introduc seri chang end week attend follow standard hand hygien practic
|
D006235;D003428
|
T058;T052;T047
|
36,270,638
|
triglycerid glucos index independ associ aortic intima media thick patient without known atherosclerot cardiovascular diseas diabet background triglycerid glucos tyg index reliabl marker insulin resist aim investig relationship tyg index aortic intima media thick imt individu without diabet mellitus atherosclerot cardiovascular diseas undergo transoesophag echocardiographi due suspect structur heart diseas method one hundr twenti two patient enrol studi januari june patient divid two group accord median imt patient imt equal less mm low imt group higher mm high imt group triglycerid glucos index higher high imt group vs p result triglycerid glucos index correl imt r p binari logist regress analysi age tyg independ associ high imt exp b ci p exp b ci p respect conclus found independ relationship tyg imt thorac aorta earli marker subclin atherosclerosi patient without known atherosclerot cardiovascular diseas diabet therefor tyg index identifi high risk subject general popul
|
D002318;D050197;D003920
|
T047;T046
|
36,270,633
|
discoveri structur activ relationship studi novel adenosin receptor select agonist seri benzyloxi phenoxi deriv adenosin receptor agonist n cyclopentyl adenosin cpa n cyclopentyl n ethylcarboxamidoadenosin cp neca synthes potenc select assess observ potent compound halogen meta posit aromat ring benzyloxi phenoxycyclopentyl substitu general neca base compound display greater r select adenosin base compound n bromobenzyloxi cyclopentyl neca n methoxyphenoxi cyclopentyl neca show fold improv r select compar neca addit quantifi compound affin kinet bind human rat r use nanobret bind assay found halogen substitu benzyloxi phenoxycyclopentyl moieti seem confer high affin r molecular model studi suggest hydrophob subpocket contribut r select display believ identifi select potent r agonist valuabl tool compound adenosin receptor research
|
D058906;D018047
|
T121;T116;T192
|
36,270,630
|
discoveri structur base design potent coval ppar invers agonist bay bay ligand activ nuclear receptor peroxisom prolifer activ receptor pparg ppar repres potenti target new generat cancer therapeut especi muscl invas lumin bladder cancer ppar critic lineag driver disclos discoveri seri chloro nitro aren coval invers agonist ppar exploit benzoxazol core improv interact corepressor ncor ncor vitro treatment sensit cell line compound result robust regul ppar target gene antiprolif effect despit imperfect physicochem properti compound show modest pharmacodynam target regul vivo improv vitro potenc efficaci bay bay compar previous describ ppar invers agonist show compound novel tool probe vitro biolog ppar invers agon
|
D047495
|
T116;T192
|
36,270,624
|
extrus print biphas anthropomorph brain phantom mimick mr relax time base algin agaros carrageenan blend avail adapt phantom mimick differ bodi part fundament establish stabil reliabl magnet reson imag mri method primari purpos phantom mimick physiolog relev contrast creat relax time head frequent examin mri anthropomorph design brain phantom would impli discrimin gray matter white matter wm within defin spatial distribut compart multichannel extrus print allow layer layer fabric multipl pastelik materi spatial defin manner predefin shape studi advantag method use fabric biphas brain phantom mimick mr relax time anthropomorph geometri printabl ink base pure natur deriv polym algin calcium cross linkabl gell agent agaros carrageenan gdcl differ concentr mol kg paramagnet compon suggest ink eg alg agar car fulfil requir viscoelast behavior printabl larg construct ml microstructur distribut gdcl assess scan electron microscopi sem energi dispers x ray spectroscopi edx close monitor step technolog develop character monophas biphas sampl printabl ink cross link gel describ construct larg scale phantom model whose relax time character check stabil time
|
D000464;D008279
|
T121;T109;T060;T059;T170;T122
|
36,270,611
|
optim design leg shape increas robust run robot rough terrain superior abil dynam leg locomot travers rough terrain relat wheel track mechan come cost fragil stabil simpl control method use basic detect sensor appli singl control help robot keep balanc travers unforeseen rough terrain exploit multipl control simultan free leg length stiff hop monopod improv robust often mechan hard implement work demonstr curv leg shape improv robust robot perturb terrain level initi horizont veloc without complic control scheme work develop spring load invert pendulum slip base model manifest coupl leg paramet captur roll motion use model find optim combin paramet maxim measur long term stabil reach desir relat height terrain demonstr travers unknown rough terrain optim coupl increas robust perturb initi horizont veloc relat optim convent slip model demonstr result experi
|
D012371;D012420
|
T090;T056
|
36,270,604
|
investig organ inorgan nanotheranost hybrid pancreat cancer therapi use cancer dish vivo model incid high aggress pancreat cancer increas across globe project increas mortal rate form cancer high relat surviv rate pancreat cancer microenviron exert major influenc poor surviv rate key factor prevent penetr chemotherapeut drug three dimension microenviron lead develop chemoresist major contributor surviv rate henc vitro studi use cultur repres better approach understand effect therapeut formul cancer cell compar convent cultur present studi explor three differ condit develop pancreat tumour spheroid model miapaca panc cell cultur day use matrigel matrix optim spheroid model employ evalu multi function nanotheranost system fabric use chitosan nanoparticl co encapsul chemotherapeut agent gemcitabin gold cap iron oxid nanoparticl multimod imag effect singl multipl dose regimen theranost system viabil spheroid form two pancreat cancer cell line studi observ tumour spheroid cultur day exhibit resist toward free gemcitabin drug unlik cultur administr multifunct nanotheranost system altern day effect reduc cancer cell viabil five dose compar group repeat dose nanotheranost system found effect singl dose cell line base differ intern carrier also reflect respons nanocarri panc show better sensit treatment vivo studi reveal combin gemcitabin magnet field induc hypothermia produc superior regress cancer compar chemotherapeut agent alon combin activ pro apoptot pathway heat induc necrosi result reveal multi function system hold promis overcom current challeng treat pancreat cancer
|
D010190;D000970
|
T121;T191;T109
|
36,270,568
|
contrast season cs concentr two stream anim share trophic nich understand season cs concentr aquat anim crucial reviv local inland fisheri season cs concentr anim expect vari even focal speci consum similar contamin food cs excret rate speci specif cs uptak forag autochthon food resourc also vari among season conduct season monitor survey dissolv cs concentr indic contamin level food resourc measur cs concentr two carnivor aquat anim palaemon pauciden rhinogobius sp share trophic nich stream connect dam reservoir dissolv cs concentr clear season high summer low winter cs concentr anim reveal differ season pattern peak octob p pauciden peak februari rhinogobius overal cs concentr relat higher p pauciden rhinogobius suggest p pauciden lower excret rate rhinogobius consequ season cs concentr p pauciden show tempor chang similar dissolv cs concentr like affect cs uptak forag wherea rhinogobius control cs excret studi show season cs concentr differ sympatr anim share trophic nich accumul knowledg compar season cs concentr fisheri speci base balanc uptak excret valuabl determin appropri season obtain less contamin product
|
D017753;D002588
|
T131;T196;T070;T082
|
36,270,567
|
associ prenat multipl plasma metal exposur newborn telomer length effect modif matern age infant sex exposur metal pregnanc may affect matern infant health howev studi combin effect metal telomer length tl newborn limit prospect cohort studi conduct among mother newborn pair guangxi zhuang birth cohort concentr metal matern plasma first trimest measur use induct coupl plasma mass spectrometri explor associ nine plasma metal newborn tl use general linear model glms princip compon analysi pca quantil g comput qgcomp bayesian kernel machin regress bkmr glms reveal invers associ plasma arsenic percent chang ci barium concentr ci newborn tl lead level relat signific decreas newborn tl femal pca reveal negat associ pc newborn tl ci bkmr joint effect metal negat associ newborn tl qgcomp indic one tertil increas metal mixtur level associ shorter newborn tl ci singl joint effect multipl metal pronounc among pregnant women carri femal fetus among pregnant women year age find suggest prenat exposur arsenic barium antimoni lead mix metal may shorten newborn tls relationship metal exposur newborn tl may exhibit heterogen accord infant sex matern age
|
D001151
|
T121;T196;T131
|
36,270,566
|
phthalat ester plastic debri abund red sea sharm obhur ecolog risk level abund plastic debri pds correl phthalic acid ester pae class pollut associ plastic well understood although pds report relat releas distribut aquat pollut pae studi link distribut pollut seawat current studi examin abund relationship pds pae seawat sharm obhur red sea estim also made ecolog impact sharm obhur semi enclos bay eastern shore red sea near jeddah saudi arabia heavili impact human activ contamin sharm obhur may transport deep water red sea subsurfac outflow pae concentr studi area rang ngl among six pae studi diethyl phthalat dep ngl di n butyl phthalat dbp ngl di ethylhexyl phthalat dehp ngl predomin addit detect across sampl sit wherea pae dimethyl phthalat dmp ngl benzyl butyl phthalat bbp ngl di n octyl phthalat dnop ngl general lower sampl sum six analyz pae pae lower sharm obhur ngl red sea shelf ngl compar red sea shelf break ngl suggest degrad adsorpt pae higher sharm obhur shelf shelf break contrast differ abund pds sharm obhur pdsm red sea shelf pdsm red sea shelf break pdsm polyethylen polypropylen domin most smaller mm major consist white black fragment fiber film posit correl pae concentr abund pds suggest either common sourc causal link leach ecolog risk pae dmp dep dbp dehp rang indic low moder risk red sea pollut index pds rang show sharm obhur site red sea suffer relat low pollut
|
D004051;D014874;D010795
|
T131;T122;T109
|
36,270,564
|
microplast pollut aquat environ may facilit misfeed fish numer recent studi document ingest microplast mps mani aquat anim yet explan misfeed fish remain unexplain test hypothesi biofilm biofoul mp surfac due exposur aquat environ facilit misfeed fish spheric polystyren ps cultur week freshwat environ grow biofilm mps goldfish employ simpl feed experi without provis genuin food ecolog relev mp concentr absorb ab proxi biofilm format increas exponenti within three week initi reach plateau approxim five week although fish swallow mps captur occur food pellet vicin signific increas probabl age durat captur also increas signific increas age result suggest drift mps aquat environ may facilit fish misidentif mps edibl prey
|
D000080545;D014874
|
T131;T122
|
36,270,563
|
juvenil arsenic exposur aggrav goblet cell hyperplasia airway mucus secret ovalbumin sensit mice gestat arsenic exposur associ advers development outcom purpos studi explor impact exposur differ period suscept allerg asthma model dam administ naaso ppm drink water throughout pregnanc lactat model newli wean pup expos naaso ppm drink water pup sensit challeng ovalbumin ova inflammatori cell infiltr pulmonari helper th cytokin upregul shown ova sensit challeng pup goblet cell hyperplasia airway mucus secret observ ova sensit challeng pup matern exposur throughout pregnanc lactat aggrav inflammatori cell infiltr airway mucus secret pulmonari th cytokin upregul ova sensit challeng pup although airway hyperreact inflammatori cell infiltr th cytokin nt influenc ova evok goblet cell hyperplasia airway mucus secret aggrav pup expos naaso wean conclus juvenil exposur increas suscept allerg asthma aggrav goblet cell hyperplasia airway mucus secret impact matern exposur pregnanc lactat suscept allerg asthma need evalu anim experi
|
D001151;D060766;D001249
|
T121;T131;T196;T047;T167
|
36,270,558
|
citrat hydroxycinnam deriv mume fructus protect lps injur intestin epitheli cell regul fakpikakt signal pathway mume fructus mf process near ripe fruit prunus mume siebold siebold zucc dri low temperatur color turn black mf often use chines medicin treatment chronic diarrhea dysenteri previous studi shown activ compon mf crohn diseas cd main citrat hydroxycinnam deriv allevi cd induc inflammatori respons intestin barrier damag howev molecular mechan cd still need elucid
|
D008070;D003424
|
T047;T109
|
36,270,545
|
cognit exercis dual task intervent amelior cognit declin natur age rat reduc oxid stress enhanc synapt plastic incid age relat cognit declin increas popul age urgent explor way amelior age relat cognit declin cognit exercis dual task intervent shown benefici effect improv cognit age cohort mechan effect remain unclear studi month old spragu dawley rat serv model natur age first perform morri water maze test chang synaptophysin content hippocampus use investig cognit declin month old rat batch month old rat treat cognit exercis cognit exercis dual task intervent week novel object recognit test use assess cognit abil enzym link immunosorb assay western blot use detect level oxid stress molecul synapt plastic relat protein found cognit exercis dual task intervent improv discrimin index natur age rat dual task intervent express level synaptophysin brain deriv neurotroph factor superoxid dismutas glutathion peroxidas increas express level lipid peroxid malondialdehyd decreas furthermor effect dual task intervent synapt plastic relat protein oxid stress indic greater singl cognit exercis intervent conclus cognit exercis dual task intervent signific amelior age relat cognit declin improv might relat reduct oxid stress enhanc synapt plastic effect cognit exercis dual task intervent may better singl cognit exercis intervent
|
D009473;D060825
|
T048;T043;T042
|
36,270,544
|
interindividu variabl adapt follow either tradit strength power train combin endur train older men secondari analysi random clinic trial studi aim investig interindividu respons follow two differ concurr train ct regimen neuromuscular cardiorespiratori function outcom older men thirti five older men year random alloc one two ct group power train pt high intens interv train hiit n tradit strength train tst hiit n maxim dynam strength one repetit maximum rm rate forc develop millisecond rdf countermov jump power cmj quadricep femori muscl thick qf mt function test sit stand time go stair climb peak oxygen consumpt vo peak assess pre post post week train chi squar test use assess differ preval respond rs non respond nrs advers respond ar similar preval individu respons rs nrs ar group observ intervent almost outcom rm power cmj qf mt function test p howev signific differ distribut rs nrs ar group observ rfd week p pt hiit group present high preval rs tst hiit vs inclus explos type contract concurr train regim induc greater respons rfd older men differ compar tradit strength train observ maxim strength muscl size vo peak function perform
|
D000076663;D055070
|
T061
|
36,270,528
|
season variat terrestri gamma dose natur radionuclid human health aim research studi season variat gamma radiat statist signific variat moreov compar situ laboratori analys uranium thorium radium potassium k content exposur low level radiat minor still contributor overal cancer risk therefor compar dose generat gamma radiat overal cancer risk research perform sw poland two granitoid massif strzelin karkonosz situ measur perform season use gamma ray spectromet exploranium bgo detector radiomet rk laboratori measur perform use spectromet hpge detector canberra packard alpha spectrometri techniqu general trend season variat natur radionuclid terrestri ambient gamma dose tgdr ambient gamma dose rate agdr difficult identifi notic slight increas valu analys paramet warmer season lower colder although except except induc precipit vari soil water content variat most statist signific statist import deviat trend regist equival uranium data survey carri intens precipit observ good posit correl situ laboratori result tgdr situlab r therefor recommend use situ measur dens measur grid collect select soil sampl better evalu level natur radiat environ averag ambient gamma dose karkonosz massif msv wherea strzelin massif msv overal cancer risk karkonoski counti higher strzelin counti connect increas gamma radiat higher overal cancer risk possibl examin elabor research
|
D014501;D012990;D011834;D009369
|
T131;T196;T191;T059
|
36,270,526
|
seed nanoprim nanomateri improv seed toler salin drought salt drought stress major environment issu world wide stress result failur seed germin limit agricultur product new approach need increas crop product ensur food safeti qualiti agricultur sustain nanoprim prime seed nanomateri emerg seed technolog improv crop product drastic climat chang associ stress factor present review provid overview nanoprim achiev salt drought toler also tri discuss behind mechan argu physico chemic properti nanomateri key factor affect negat posit effect seed germin term seed nanoprim furthermor highlight possibl critic role seed coat anatomi effect nanoprim term save cost reduc biosafeti issu review aim help research better understand follow fast develop cost effect environment friend research area
|
D018525;D049329
|
T073;T038
|
36,270,525
|
effect polystyren nanoplast differ function group accumul toxic pb dandelion micro nano plastic ubiquit environ potenti affect toxic effect chemic heavi metal although interact micro nano plastic heavi metal well effect aquat organ wide investig studi influenc terrestri plant limit therefor studi effect polystyren ps carboxi modifi ps cps amino modifi ps ap nanoparticl accumul toxic pb dandelion taraxacum asiaticum dahlst investig use hydropon cultiv presenc three ps caus cell damag destroy tertiari structur ribulos bisphosph carboxylaseoxygenas rubisco dehydrogenas dha enzym therebi inhibit rubisco root activ hinder nutrient uptak photosynthesi inhibit ap biomass dandelion greater ps cps confoc laser scan microscop transmiss electron microscopi analysi show ap like enter root dandelion ps cps presenc pb induc ps cps ap enter dandelion root pb aggrav ps cps toxic dandelion rather ap toxic complex form cps pb affect structur rubisco dha coval coordin bond pb increas surfac posit charg cps accord gaussian analysi presenc ps cps signific reduc pb uptak dandelion exacerb toxic pb contrast ap slight inhibit pb accumul aggrav pb toxic dandelion find reveal chang uptak nanoplast pb dandelion potenti result cascad event increas toxic inhibit growth dandelion seedl
|
D011137;D031205
|
T122;T002;T109
|
36,270,524
|
mitig biofoul co deposit polydopamin curcumin surfac thin film composit membran revers osmosi ro membran wide use various water treatment field effici desalin technolog serious biofoul problem aris actual applic process curcumin known natur compound reduc biofoul inhibit growth microorgan base quorum sens dopamin molecul excel adhes function materi surfac high research valu appli curcumin coat membran surfac curcumin degrad alkalin condit wherea dopamin must polymer alkalin condit simultan coat may advers affect curcumin therefor two step coat process consid self polymer dopamin thin film composit membran surfac dip coat curcumin attach polydopamin layer furthermor effect time concentr surfac modif membran modif investig highest permeabl lm hrbar achiev modifi membran number gram posit bacteria decreas cfuml result meaning antifoul modif membran surfac use curcumin appli reduc biofoul extend lifetim membran without pretreat membran clean
|
D057219;D003474;D018508
|
T121;T070;T109;T052;T130;T057
|
36,270,523
|
laboratori rill studi imx transport overland flow deposit explos contamin particul form onto soil surfac low order deton lead ground surfac water contamin vertic fate transport insensit munit formul imx soil thorough studi howev later transport explos particl surfac less known object research understand impact overland flow transport imx constitu compound nitro triazol one nto dinitroanisol dnan hexahydro trinitro triazin rdx octahydro tetranitro tetrazocin hmx effect overland flow examin rill flume use sever flow rate ml min imx particl size mm mm mm mm found smaller particl transport solut sediment compar larger particl higher percent mass remain surfac flow rate increas increas percent mass found solut sediment decreas percent mass remain surfac nto fate domin transport solut dnan rdx hmx predomin transport sediment research provid evid role overland flow fate energet compound
|
D009574;D053834
|
T120;T109
|
36,270,522
|
advanc photocatalyt steril recalcitr enterococcus sp contamin water newli develop z scheme bi wo base composit solar light pathogen contamin one major caus clean water shortag pose great risk human health herein g c n cn first introduc agag obipo bi wo agpbwo construct novel z scheme composit cn agpbwo disinfect enterococcus sp contamin water cn agpbwo show excel disinfect perform toward recalcitr enterococcus sp simul solar light irradi achiev complet inactiv cfu ml bacteri cell within min main attribut improv light absorpt abil charg carri separationtransf effici surfac wettabl addit disinfect mechan cn agpbwo toward enterococcus sp systemat investig photogener activ speci h oh work togeth play crucial role photocatalyt inactiv antioxid system enabl enterococcus sp self protect abil begin disinfect secret antioxid enzym howev accumul activ speci bacteri cell membran energi system damag led leakag intracellular compon decomposit bacteria besid cn agpbwo exhibit high practic differ environment factor also perform well real lake water disinfect high stabil confirm practic water disinfect work systemat reveal disinfect mechan toward enterococcus sp also provid effici method water disinfect
|
D016983;D008027
|
T007;T070
|
36,270,520
|
effect immobil cd ii soil biotic zero valent iron coexist sulfat work zero valent iron zvi combin anaerob bacteria use remedi cd ii pollut soil mediat sulfat owe hydrogen autotroph sulfat reduct serious corros occur sulfat mediat biotic zvi term solid phase character massiv corros product eg goethit magnetit green rust form crucial immobil cd ii thus integr system achiev fold increas aqueous cd ii remov convert easili avail cd ii fraction acid extract reduc stabl form oxidiz residu base sequenti extract result compar sulfat mediat zvi system increas concentr zvi dosag demonstr posit correl cd ii immobil reflect hydrogenotroph desulfur act essenti role improv cd ii immobil indic hydrogenotroph desulfur could acceler iron corros promot reactiv miner format biominer well generat cadmium sulfid precipit cds achiev excel immobil perform cd ii besid reaction favor neutral ph condit result highlight promot effect hydrogen autotroph desulfur zvi corros immobil cd ii offer practic techniqu cd ii pollut soil remedi
|
D007501;D012987
|
T123;T196;T121;T167
|
36,270,510
|
provis black soldier fli larva hermetia illucen differ way benefit broiler welfar perform largest effect scatter live larva includ black soldier fli larva bsfl broiler diet potenti benefit broiler welfar increas product perform effect dietari bsfl like depend way bsfl provid studi aim discern effect differ bsfl form provis method provid male broiler bsfl con process bsfl meal oil incorpor feed pellet inc f dri bsfl feeder top feed f dri live bsfl scatter pen l respect evalu various indic broiler welfar product perform dietari bsfl treatment total dietari dri matter content replac bsfl dri live larva provid four equal daili portion compar diet without bsfl scatter dri live larva pen increas activ behavior though live larva increas time broiler spent stand broiler f l treatment higher averag daili bodi weight gain period higher final weight despit l broiler lower total dri matter intak con broiler furthermor dri matter convers ratio inc f l broiler reduc end rear period pen dietari bsfl treatment better litter qualiti con pen furthermor food pad dermat less sever inc f broiler con broiler l broiler broiler treatment hock burn sever less l con broiler broiler lame cleanli plasma natur antibodi titer whole blood serotonin influenc dietari bsfl treatment feather corticosteron concentr affect treatment though without signific post hoc differ result indic bsfl meal oil dri live bsfl promis feed ingredi broiler benefit aspect broiler welfar product perform scatter bsfl pen result welfar benefit provid bsfl feeder live bsfl benefici effect broiler welfar
|
D002645;D004175
|
T204;T012
|
36,270,509
|
investig role orexin cocain amphetamin regul transcript nucleus accumben shell bing eat male rat relationship impuls bing eat disord bed preval eat disord adult popul character recurr episod uncontrol overconsumpt palat food pf bed connect sever comorbid obes major depress substanc use disord link heighten level impuls neurobiolog basi bed howev still vagu known bing eat occur without homeostat need therefor relat hedon consumpt pf major brain structur control hedon feed part network regul impuls action nucleus accumben shell nacsh present studi rat assess influenc trait impuls develop like feed role orexigen neuropeptid orexin ox anorexigen neuropeptid cocain amphetamin regul transcript cart within nacsh model rat initi rank trait impuls base screen choic serial reaction time task subsequ introduc limit access model establish like feed pure veget fat examin correl trait impuls develop like feed effect bilater infus ox receptor oxr antagonist sb sb cart antibodi cart ab nacsh examin relat trait impuls accumb oxr densiti evalu immunohistochem stain rat normal like feed behavior found anim develop stabl like pf intak independ trait impuls without differ dynam blockad accumb oxr effect reduc pf intak control group daili access pf impuls trait decis factor point toward alter orexinerg transmiss nacsh rat bing pure fat corrobor lower densiti oxr nacsh rat like feed behavior precis low impuls bing rat regardless impuls trait antagon cart nacsh affect pf intak control bing anim suggest endogen accumb cart influenc consummatori behavior ad libitum fed rat access fat normal like feed pattern
|
D056912;D002032;D009479;D003042
|
T123;T121;T116;T109;T131;T048
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.